Impact of Price Control Measures on Medicine Access in Canada

Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death in the United States, and 73% in 26 high-income countries Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death in the United States, and 73% in 26 high-income countries

The Montreal Economic Institute (MEI) has published a report warning that price control measures on pharmaceuticals, particularly the Most Favored Nation (MFN) Drug Pricing policy, can significantly hinder access to new medicines in Canada. The implementation of such policies is designed to regulate drug prices in order to make health care more affordable; however, the MEI argues that these measures can lead to unintended negative consequences for innovation and patient access.

The MFN policy essentially dictates that the prices of drugs in Canada should not exceed the lowest price available in other comparable countries. Although this might seem beneficial at first glance, the report outlines several critical drawbacks. It suggests that by capping the prices of new drugs, pharmaceutical companies may be deterred from investing in research and development. The potential decrease in market attractiveness could lead to fewer new drugs being introduced, ultimately affecting patients who rely on these innovations for better treatments and therapies.

The MEI points to evidence indicating a negative correlation between price controls and the availability of new medication, particularly in countries where such regulations are stringent. When companies perceive a lesser return on investment, it may lead them to prioritize markets that promise higher profits, consequently delaying or completely sidelining new drug launches in Canada.

Furthermore, the report emphasizes that the sustainability of Canada’s healthcare system could be jeopardized by reduced access to cutting-edge treatments. With the rapidly evolving nature of healthcare needs, especially following the COVID-19 pandemic, having robust access to new and innovative medications is crucial. Price controls might provide short-term savings for the government and consumers, but in the long term, they could severely limit treatment options and overall health outcomes.

In response to these findings, MEI advocates for revisiting price control mandates and suggests exploring alternative strategies to support affordability without compromising access to new medicines. This includes potential reforms that prioritize long-term health outcomes over immediate fiscal savings. It’s suggested that governments work collaboratively with the pharmaceutical industry to establish a more conducive environment for drug development while ensuring that Canadians continue to benefit from the latest advancements in medicine.